Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 49 entries
Sorted by: Best Match Show Resources per page
Precision Microfilters as an all in one System for Multiplex Analysis of Circulating Tumor Cells.

RSC advances

Adams DL, Alpaugh RK, Martin SS, Charpentier M, Chumsri S, Cristofanilli M, Adams DK, Makarova OV, Zhu P, Li S, Tang CM, Stefansson S.
PMID: 29093811
RSC Adv. 2016;6(8):6405-6414. doi: 10.1039/c5ra21524b. Epub 2016 Jan 11.

Enumeration of circulating tumor cells (CTCs) from cancer patient blood is an established diagnostic assay used to evaluate patient status as a singleplex test. However, in the coming age of personalized medicine, multiplex analysis of patient CTCs, including proteomic...

Cite
Adams DL, Alpaugh RK, Martin SS, et al. Precision Microfilters as an all in one System for Multiplex Analysis of Circulating Tumor Cells. RSC Adv. 2016;6(8):6405-6414doi: 10.1039/c5ra21524b.
Adams, D. L., Alpaugh, R. K., Martin, S. S., Charpentier, M., Chumsri, S., Cristofanilli, M., Adams, D. K., Makarova, O. V., Zhu, P., Li, S., Tang, C. M., & Stefansson, S. (2016). Precision Microfilters as an all in one System for Multiplex Analysis of Circulating Tumor Cells. RSC advances, 6(8), 6405-6414. https://doi.org/10.1039/c5ra21524b
Adams, Daniel L, et al. "Precision Microfilters as an all in one System for Multiplex Analysis of Circulating Tumor Cells." RSC advances vol. 6,8 (2016): 6405-6414. doi: https://doi.org/10.1039/c5ra21524b
Adams DL, Alpaugh RK, Martin SS, Charpentier M, Chumsri S, Cristofanilli M, Adams DK, Makarova OV, Zhu P, Li S, Tang CM, Stefansson S. Precision Microfilters as an all in one System for Multiplex Analysis of Circulating Tumor Cells. RSC Adv. 2016;6(8):6405-6414. doi: 10.1039/c5ra21524b. Epub 2016 Jan 11. PMID: 29093811; PMCID: PMC5662211.
Copy Download .nbib Format: NLM
International Consensus on the Clinical Management of Inflammatory Breast Cancer from the Morgan Welch Inflammatory Breast Cancer Research Program 10th Anniversary Conference.

Journal of Cancer

Ueno NT, Espinosa Fernandez JR, Cristofanilli M, Overmoyer B, Rea D, Berdichevski F, El-Shinawi M, Bellon J, Le-Petross HT, Lucci A, Babiera G, DeSnyder SM, Teshome M, Chang E, Lim B, Krishnamurthy S, Stauder MC, Parmar S, Mohamed MM, Alexander A, Valero V, Woodward WA.
PMID: 29721054
J Cancer. 2018 Apr 06;9(8):1437-1447. doi: 10.7150/jca.23969. eCollection 2018.

National and international experts in inflammatory breast cancer (IBC) from high-volume centers treating IBC recently convened at the 10th Anniversary Conference of the Morgan Welch Inflammatory Breast Cancer Research Program at The University of Texas MD Anderson Cancer Center...

Cite
Ueno NT, Espinosa Fernandez JR, Cristofanilli M, et al. International Consensus on the Clinical Management of Inflammatory Breast Cancer from the Morgan Welch Inflammatory Breast Cancer Research Program 10th Anniversary Conference. J Cancer. 2018;9(8):1437-1447doi: 10.7150/jca.23969.
Ueno, N. T., Espinosa Fernandez, J. R., Cristofanilli, M., Overmoyer, B., Rea, D., Berdichevski, F., El-Shinawi, M., Bellon, J., Le-Petross, H. T., Lucci, A., Babiera, G., DeSnyder, S. M., Teshome, M., Chang, E., Lim, B., Krishnamurthy, S., Stauder, M. C., Parmar, S., Mohamed, M. M., Alexander, A., Valero, V., & Woodward, W. A. (2018). International Consensus on the Clinical Management of Inflammatory Breast Cancer from the Morgan Welch Inflammatory Breast Cancer Research Program 10th Anniversary Conference. Journal of Cancer, 9(8), 1437-1447. https://doi.org/10.7150/jca.23969
Ueno, Naoto T, et al. "International Consensus on the Clinical Management of Inflammatory Breast Cancer from the Morgan Welch Inflammatory Breast Cancer Research Program 10th Anniversary Conference." Journal of Cancer vol. 9,8 (2018): 1437-1447. doi: https://doi.org/10.7150/jca.23969
Ueno NT, Espinosa Fernandez JR, Cristofanilli M, Overmoyer B, Rea D, Berdichevski F, El-Shinawi M, Bellon J, Le-Petross HT, Lucci A, Babiera G, DeSnyder SM, Teshome M, Chang E, Lim B, Krishnamurthy S, Stauder MC, Parmar S, Mohamed MM, Alexander A, Valero V, Woodward WA. International Consensus on the Clinical Management of Inflammatory Breast Cancer from the Morgan Welch Inflammatory Breast Cancer Research Program 10th Anniversary Conference. J Cancer. 2018 Apr 06;9(8):1437-1447. doi: 10.7150/jca.23969. eCollection 2018. PMID: 29721054; PMCID: PMC5929089.
Copy Download .nbib Format: NLM
Scientific Summary from the Morgan Welch MD Anderson Cancer Center Inflammatory Breast Cancer (IBC) Program 10.

Journal of Cancer

Woodward WA, Cristofanilli M, Merajver SD, Van Laere S, Pusztai L, Bertucci F, Berditchevski F, Polyak K, Overmoyer B, Devi GR, Sterneck E, Schneider R, Debeb BG, Wang X, van Golen KL, El-Zein R, Rahal OM, Alexander A, Reuben JM, Krishnamurthy S, Lucci A, Ueno NT.
PMID: 29667990
J Cancer. 2017 Oct 09;8(17):3607-3614. doi: 10.7150/jca.21200. eCollection 2017.

In 2006, a remarkable collaboration between University of Texas MD Anderson Cancer Center clinicians and Texas and New Mexico State legislators led to the formation of a dedicated IBC Research Program and Clinic at MD Anderson. This initiative provided...

Cite
Woodward WA, Cristofanilli M, Merajver SD, et al. Scientific Summary from the Morgan Welch MD Anderson Cancer Center Inflammatory Breast Cancer (IBC) Program 10. J Cancer. 2017;8(17):3607-3614doi: 10.7150/jca.21200.
Woodward, W. A., Cristofanilli, M., Merajver, S. D., Van Laere, S., Pusztai, L., Bertucci, F., Berditchevski, F., Polyak, K., Overmoyer, B., Devi, G. R., Sterneck, E., Schneider, R., Debeb, B. G., Wang, X., van Golen, K. L., El-Zein, R., Rahal, O. M., Alexander, A., Reuben, J. M., Krishnamurthy, S., Lucci, A., & Ueno, N. T. (2017). Scientific Summary from the Morgan Welch MD Anderson Cancer Center Inflammatory Breast Cancer (IBC) Program 10. Journal of Cancer, 8(17), 3607-3614. https://doi.org/10.7150/jca.21200
Woodward, Wendy A, et al. "Scientific Summary from the Morgan Welch MD Anderson Cancer Center Inflammatory Breast Cancer (IBC) Program 10." Journal of Cancer vol. 8,17 (2017): 3607-3614. doi: https://doi.org/10.7150/jca.21200
Woodward WA, Cristofanilli M, Merajver SD, Van Laere S, Pusztai L, Bertucci F, Berditchevski F, Polyak K, Overmoyer B, Devi GR, Sterneck E, Schneider R, Debeb BG, Wang X, van Golen KL, El-Zein R, Rahal OM, Alexander A, Reuben JM, Krishnamurthy S, Lucci A, Ueno NT. Scientific Summary from the Morgan Welch MD Anderson Cancer Center Inflammatory Breast Cancer (IBC) Program 10. J Cancer. 2017 Oct 09;8(17):3607-3614. doi: 10.7150/jca.21200. eCollection 2017. PMID: 29667990; PMCID: PMC5687177.
Copy Download .nbib Format: NLM
Molecular dissection of cancers - another piece in the puzzle to better assess, and treat, disease using biomarkers that correlate with disease type and stage.

Personalized medicine

Frueh F, Issa A, Andreopoulou E, Cristofanilli M.
PMID: 29783493
Per Med. 2008 May;5(3):211-213. doi: 10.2217/17410541.5.3.211.

No abstract available.

Cite
Frueh F, Issa A, Andreopoulou E, et al. Molecular dissection of cancers - another piece in the puzzle to better assess, and treat, disease using biomarkers that correlate with disease type and stage. Per Med. 2008;5(3):211-213doi: 10.2217/17410541.5.3.211.
Frueh, F., Issa, A., Andreopoulou, E., & Cristofanilli, M. (2008). Molecular dissection of cancers - another piece in the puzzle to better assess, and treat, disease using biomarkers that correlate with disease type and stage. Personalized medicine, 5(3), 211-213. https://doi.org/10.2217/17410541.5.3.211
Frueh, Felix, et al. "Molecular dissection of cancers - another piece in the puzzle to better assess, and treat, disease using biomarkers that correlate with disease type and stage." Personalized medicine vol. 5,3 (2008): 211-213. doi: https://doi.org/10.2217/17410541.5.3.211
Frueh F, Issa A, Andreopoulou E, Cristofanilli M. Molecular dissection of cancers - another piece in the puzzle to better assess, and treat, disease using biomarkers that correlate with disease type and stage. Per Med. 2008 May;5(3):211-213. doi: 10.2217/17410541.5.3.211. PMID: 29783493.
Copy Download .nbib Format: NLM
Antineoplastic effects of selective CDK9 inhibition with atuveciclib on cancer stem-like cells in triple-negative breast cancer.

Oncotarget

Brisard D, Eckerdt F, Marsh LA, Blyth GT, Jain S, Cristofanilli M, Horiuchi D, Platanias LC.
PMID: 30647871
Oncotarget. 2018 Dec 18;9(99):37305-37318. doi: 10.18632/oncotarget.26468. eCollection 2018 Dec 18.

Treatment options for triple-negative breast cancer (TNBC) are limited due to the lack of efficient targeted therapies, frequently resulting in recurrence and metastatic disease. Accumulating evidence suggests that a small population of cancer stem-like cells (CSLCs) is responsible for...

Cite
Brisard D, Eckerdt F, Marsh LA, et al. Antineoplastic effects of selective CDK9 inhibition with atuveciclib on cancer stem-like cells in triple-negative breast cancer. Oncotarget. 2018;9(99):37305-37318doi: 10.18632/oncotarget.26468.
Brisard, D., Eckerdt, F., Marsh, L. A., Blyth, G. T., Jain, S., Cristofanilli, M., Horiuchi, D., & Platanias, L. C. (2018). Antineoplastic effects of selective CDK9 inhibition with atuveciclib on cancer stem-like cells in triple-negative breast cancer. Oncotarget, 9(99), 37305-37318. https://doi.org/10.18632/oncotarget.26468
Brisard, Daphne, et al. "Antineoplastic effects of selective CDK9 inhibition with atuveciclib on cancer stem-like cells in triple-negative breast cancer." Oncotarget vol. 9,99 (2018): 37305-37318. doi: https://doi.org/10.18632/oncotarget.26468
Brisard D, Eckerdt F, Marsh LA, Blyth GT, Jain S, Cristofanilli M, Horiuchi D, Platanias LC. Antineoplastic effects of selective CDK9 inhibition with atuveciclib on cancer stem-like cells in triple-negative breast cancer. Oncotarget. 2018 Dec 18;9(99):37305-37318. doi: 10.18632/oncotarget.26468. eCollection 2018 Dec 18. PMID: 30647871; PMCID: PMC6324664.
Copy Download .nbib Format: NLM
Current state of clinical trials in breast cancer brain metastases.

Neuro-oncology practice

Fares J, Kanojia D, Cordero A, Rashidi A, Miska J, Schwartz CW, Savchuk S, Ahmed AU, Balyasnikova IV, Cristofanilli M, Gradishar WJ, Lesniak MS.
PMID: 31555454
Neurooncol Pract. 2019 Sep;6(5):392-401. doi: 10.1093/nop/npz003. Epub 2019 Feb 11.

BACKGROUND: Breast cancer brain metastases (BCBM) are the final frontier in neuro-oncology for which more efficacious therapies are required. In this work, we explore clinical trials in BCBM, and determine the shortcomings in the development of new BCBM therapies...

Cite
Fares J, Kanojia D, Cordero A, et al. Current state of clinical trials in breast cancer brain metastases. Neurooncol Pract. 2019;6(5):392-401doi: 10.1093/nop/npz003.
Fares, J., Kanojia, D., Cordero, A., Rashidi, A., Miska, J., Schwartz, C. W., Savchuk, S., Ahmed, A. U., Balyasnikova, I. V., Cristofanilli, M., Gradishar, W. J., & Lesniak, M. S. (2019). Current state of clinical trials in breast cancer brain metastases. Neuro-oncology practice, 6(5), 392-401. https://doi.org/10.1093/nop/npz003
Fares, Jawad, et al. "Current state of clinical trials in breast cancer brain metastases." Neuro-oncology practice vol. 6,5 (2019): 392-401. doi: https://doi.org/10.1093/nop/npz003
Fares J, Kanojia D, Cordero A, Rashidi A, Miska J, Schwartz CW, Savchuk S, Ahmed AU, Balyasnikova IV, Cristofanilli M, Gradishar WJ, Lesniak MS. Current state of clinical trials in breast cancer brain metastases. Neurooncol Pract. 2019 Sep;6(5):392-401. doi: 10.1093/nop/npz003. Epub 2019 Feb 11. PMID: 31555454; PMCID: PMC6753353.
Copy Download .nbib Format: NLM
IMPassionate about immunotherapy for TNBC: from change, to revolution and to cure?.

Annals of translational medicine

Vagia E, Cristofanilli M.
PMID: 33313282
Ann Transl Med. 2020 Nov;8(22):1537. doi: 10.21037/atm-20-3690.

No abstract available.

Cite
Vagia E, Cristofanilli M. IMPassionate about immunotherapy for TNBC: from change, to revolution and to cure?. Ann Transl Med. 2020;8(22):1537doi: 10.21037/atm-20-3690.
Vagia, E., & Cristofanilli, M. (2020). IMPassionate about immunotherapy for TNBC: from change, to revolution and to cure?. Annals of translational medicine, 8(22), 1537. https://doi.org/10.21037/atm-20-3690
Vagia, Elena, and Cristofanilli, Massimo. "IMPassionate about immunotherapy for TNBC: from change, to revolution and to cure?." Annals of translational medicine vol. 8,22 (2020): 1537. doi: https://doi.org/10.21037/atm-20-3690
Vagia E, Cristofanilli M. IMPassionate about immunotherapy for TNBC: from change, to revolution and to cure?. Ann Transl Med. 2020 Nov;8(22):1537. doi: 10.21037/atm-20-3690. PMID: 33313282; PMCID: PMC7729326.
Copy Download .nbib Format: NLM
Comparative effectiveness of first-line palbociclib plus letrozole versus letrozole alone for HR+/HER2- metastatic breast cancer in US real-world clinical practice.

Breast cancer research : BCR

DeMichele A, Cristofanilli M, Brufsky A, Liu X, Mardekian J, McRoy L, Layman RM, Emir B, Torres MA, Rugo HS, Finn RS.
PMID: 33761995
Breast Cancer Res. 2021 Mar 24;23(1):37. doi: 10.1186/s13058-021-01409-8.

BACKGROUND: Findings from randomized clinical trials may have limited generalizability to patients treated in routine clinical practice. This study examined the effectiveness of first-line palbociclib plus letrozole versus letrozole alone on survival outcomes in patients with hormone receptor-positive (HR+)/human...

Cite
DeMichele A, Cristofanilli M, Brufsky A, et al. Comparative effectiveness of first-line palbociclib plus letrozole versus letrozole alone for HR+/HER2- metastatic breast cancer in US real-world clinical practice. Breast Cancer Res. 2021;23(1):37doi: 10.1186/s13058-021-01409-8.
DeMichele, A., Cristofanilli, M., Brufsky, A., Liu, X., Mardekian, J., McRoy, L., Layman, R. M., Emir, B., Torres, M. A., Rugo, H. S., & Finn, R. S. (2021). Comparative effectiveness of first-line palbociclib plus letrozole versus letrozole alone for HR+/HER2- metastatic breast cancer in US real-world clinical practice. Breast cancer research : BCR, 23(1), 37. https://doi.org/10.1186/s13058-021-01409-8
DeMichele, Angela, et al. "Comparative effectiveness of first-line palbociclib plus letrozole versus letrozole alone for HR+/HER2- metastatic breast cancer in US real-world clinical practice." Breast cancer research : BCR vol. 23,1 (2021): 37. doi: https://doi.org/10.1186/s13058-021-01409-8
DeMichele A, Cristofanilli M, Brufsky A, Liu X, Mardekian J, McRoy L, Layman RM, Emir B, Torres MA, Rugo HS, Finn RS. Comparative effectiveness of first-line palbociclib plus letrozole versus letrozole alone for HR+/HER2- metastatic breast cancer in US real-world clinical practice. Breast Cancer Res. 2021 Mar 24;23(1):37. doi: 10.1186/s13058-021-01409-8. PMID: 33761995; PMCID: PMC7989035.
Copy Download .nbib Format: NLM
Environmental conditions at the South Col of Mount Everest and their impact on hypoxia and hypothermia experienced by mountaineers.

Extreme physiology & medicine

Moore K, Semple J, Cristofanelli P, Bonasoni P, Stocchi P.
PMID: 23849229
Extrem Physiol Med. 2012 Sep 04;1(1):2. doi: 10.1186/2046-7648-1-2.

BACKGROUND: Hypoxia and hypothermia are acknowledged risk factors for those who venture into high-altitude regions. There is, however, little in situ data that can be used to quantify these risks. Here, we use 7 months of continuous meteorological data...

Cite
Moore K, Semple J, Cristofanelli P, et al. Environmental conditions at the South Col of Mount Everest and their impact on hypoxia and hypothermia experienced by mountaineers. Extrem Physiol Med. 2012;1(1):2doi: 10.1186/2046-7648-1-2.
Moore, K., Semple, J., Cristofanelli, P., Bonasoni, P., & Stocchi, P. (2012). Environmental conditions at the South Col of Mount Everest and their impact on hypoxia and hypothermia experienced by mountaineers. Extreme physiology & medicine, 1(1), 2. https://doi.org/10.1186/2046-7648-1-2
Moore, Kent, et al. "Environmental conditions at the South Col of Mount Everest and their impact on hypoxia and hypothermia experienced by mountaineers." Extreme physiology & medicine vol. 1,1 (2012): 2. doi: https://doi.org/10.1186/2046-7648-1-2
Moore K, Semple J, Cristofanelli P, Bonasoni P, Stocchi P. Environmental conditions at the South Col of Mount Everest and their impact on hypoxia and hypothermia experienced by mountaineers. Extrem Physiol Med. 2012 Sep 04;1(1):2. doi: 10.1186/2046-7648-1-2. PMID: 23849229; PMCID: PMC3707097.
Copy Download .nbib Format: NLM
Advancements in the Treatment of Metastatic Breast Cancer (MBC): The Role of Ixabepilone.

Journal of oncology

Cristofanilli M.
PMID: 22645612
J Oncol. 2012;2012:703858. doi: 10.1155/2012/703858. Epub 2012 May 08.

Successful management of breast cancer in the metastatic setting is often confounded by resistance to chemotherapeutics, in particular anthracyclines and taxanes. The limited number of effective treatment options for patients with more aggressive biological subtypes, such as triple-negative metastatic...

Cite
Cristofanilli M. Advancements in the Treatment of Metastatic Breast Cancer (MBC): The Role of Ixabepilone. J Oncol. 2012;2012:703858doi: 10.1155/2012/703858.
Cristofanilli, M. (2012). Advancements in the Treatment of Metastatic Breast Cancer (MBC): The Role of Ixabepilone. Journal of oncology, 2012703858. https://doi.org/10.1155/2012/703858
Cristofanilli, Massimo. "Advancements in the Treatment of Metastatic Breast Cancer (MBC): The Role of Ixabepilone." Journal of oncology vol. 2012 (2012): 703858. doi: https://doi.org/10.1155/2012/703858
Cristofanilli M. Advancements in the Treatment of Metastatic Breast Cancer (MBC): The Role of Ixabepilone. J Oncol. 2012;2012:703858. doi: 10.1155/2012/703858. Epub 2012 May 08. PMID: 22645612; PMCID: PMC3356906.
Copy Download .nbib Format: NLM
The role of circulating tumor cells in breast cancer diagnosis and prediction of therapy response.

Expert opinion on medical diagnostics

Reuben JM, Krishnamurthy S, Woodward W, Cristofanilli M.
PMID: 23495703
Expert Opin Med Diagn. 2008 Apr;2(4):339-48. doi: 10.1517/17530059.2.4.339.

BACKGROUND: Metastatic breast cancer (MBC) is incurable and any treatment is considered palliative. Occult dissemination of tumor cells is responsible for recurrent MBC in patients who have undergone resection of their primary tumor. The presence of circulating tumor cells...

Cite
Reuben JM, Krishnamurthy S, Woodward W, et al. The role of circulating tumor cells in breast cancer diagnosis and prediction of therapy response. Expert Opin Med Diagn. 2008;2(4):339-48doi: 10.1517/17530059.2.4.339.
Reuben, J. M., Krishnamurthy, S., Woodward, W., & Cristofanilli, M. (2008). The role of circulating tumor cells in breast cancer diagnosis and prediction of therapy response. Expert opinion on medical diagnostics, 2(4), 339-48. https://doi.org/10.1517/17530059.2.4.339
Reuben, James M, et al. "The role of circulating tumor cells in breast cancer diagnosis and prediction of therapy response." Expert opinion on medical diagnostics vol. 2,4 (2008): 339-48. doi: https://doi.org/10.1517/17530059.2.4.339
Reuben JM, Krishnamurthy S, Woodward W, Cristofanilli M. The role of circulating tumor cells in breast cancer diagnosis and prediction of therapy response. Expert Opin Med Diagn. 2008 Apr;2(4):339-48. doi: 10.1517/17530059.2.4.339. PMID: 23495703.
Copy Download .nbib Format: NLM
Circulating Tumor Cells (CTC) Are Associated with Defects in Adaptive Immunity in Patients with Inflammatory Breast Cancer.

Journal of Cancer

Mego M, Gao H, Cohen EN, Anfossi S, Giordano A, Sanda T, Fouad TM, De Giorgi U, Giuliano M, Woodward WA, Alvarez RH, Valero V, Ueno NT, Hortobagyi GN, Cristofanilli M, Reuben JM.
PMID: 27326253
J Cancer. 2016 Jun 03;7(9):1095-104. doi: 10.7150/jca.13098. eCollection 2016.

BACKGROUND: Circulating tumor cells (CTCs) play a crucial role in tumor dissemination and are prognostic in primary and metastatic breast cancer. Peripheral blood (PB) immune cells contribute to an unfavorable microenvironment for CTC survival. This study aimed to correlate...

Cite
Mego M, Gao H, Cohen EN, et al. Circulating Tumor Cells (CTC) Are Associated with Defects in Adaptive Immunity in Patients with Inflammatory Breast Cancer. J Cancer. 2016;7(9):1095-104doi: 10.7150/jca.13098.
Mego, M., Gao, H., Cohen, E. N., Anfossi, S., Giordano, A., Sanda, T., Fouad, T. M., De Giorgi, U., Giuliano, M., Woodward, W. A., Alvarez, R. H., Valero, V., Ueno, N. T., Hortobagyi, G. N., Cristofanilli, M., & Reuben, J. M. (2016). Circulating Tumor Cells (CTC) Are Associated with Defects in Adaptive Immunity in Patients with Inflammatory Breast Cancer. Journal of Cancer, 7(9), 1095-104. https://doi.org/10.7150/jca.13098
Mego, M, et al. "Circulating Tumor Cells (CTC) Are Associated with Defects in Adaptive Immunity in Patients with Inflammatory Breast Cancer." Journal of Cancer vol. 7,9 (2016): 1095-104. doi: https://doi.org/10.7150/jca.13098
Mego M, Gao H, Cohen EN, Anfossi S, Giordano A, Sanda T, Fouad TM, De Giorgi U, Giuliano M, Woodward WA, Alvarez RH, Valero V, Ueno NT, Hortobagyi GN, Cristofanilli M, Reuben JM. Circulating Tumor Cells (CTC) Are Associated with Defects in Adaptive Immunity in Patients with Inflammatory Breast Cancer. J Cancer. 2016 Jun 03;7(9):1095-104. doi: 10.7150/jca.13098. eCollection 2016. PMID: 27326253; PMCID: PMC4911877.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 49 entries